1. Report Overview
1.1 Overview of the World Vaccines Market
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to the World Human Vaccines Market
2.1 Human Vaccines - Aiming for Global Disease Prevention
2.2 What is the Social and Economic Burden?
2.3 Vaccine Technology
2.3.1 Inactivated Vaccines
2.3.2 Live Attenuated Vaccines
2.3.3 Conjugate Vaccines
2.3.4 Recombinant Vector Vaccines
2.4 Key Influencers of the Human Vaccine Market
2.4.1 Governments and International Organizations
2.4.1.1 The World Health Organisation (WHO)
2.4.1.2 The Governmental Influence
2.4.2 Leading Manufacturers
2.4.2.1 Merck & Co.
2.4.2.2 Sanofi
2.4.2.3 GlaxoSmithKline
2.4.2.4 Pfizer
2.5 Human World Vaccines – Market Segmentation
2.5.1 Paediatric Vaccines
2.5.2 Adult Vaccines
2.5.3 Elderly Vaccines
2.5.4 Travel Vaccines
2.5.5 Therapeutic Vaccines
3. World Vaccine Market Outlook, 2016-2026
3.1 World Vaccine Market, 2015
3.1.1 Paediatric Vaccines Maintains Constant Demand
3.1.2 Ageing Population Requires More Care
3.1.3 Emerging Markets Demand Better Immunity
3.2 The World Human Vaccines Forecast, 2016-2026
3.3 The World Vaccine Market: Industry Trends, 2016-2026
3.3.1 Undulating Demand
3.3.2 Supply Restraints
3.3.3 Funding Trends
3.3.4 Protecting the Workforce of an Economy
4. World Vaccine Submarkets: Prospects, 2016-2026
4.1 Paediatric Vaccines
4.1.1 Paediatric Vaccine Forecast, 2016-2026
4.1.2 Paediatric Vaccine Trends
4.1.2.1 Innovative Delivery
4.1.2.2 Fear Factor
4.1.2.3 Novel Vectors
4.2 Adult Vaccines
4.2.1 Adult Vaccine Forecast, 2016-2026
4.2.2 Adult Vaccine Trends
4.2.2.1 Fighting the Flu
4.2.2.2 HPV
4.2.2.3 Repeat Doses for Continued Protection
4.3 Elderly Vaccines
4.3.1 Elderly Vaccine Forecast, 2016-2026
4.3.2 Elderly Vaccine Trends
4.3.2.1 With Age Comes Greater Risk
4.3.2.2 Ageing Population across the Globe
4.4 Travel Vaccines
4.4.1 Travel Vaccines Forecast, 2016-2026
4.4.2 Travel Vaccine Trends
4.4.2.1 Zika Virus Outbreak
4.4.2.2 Globalization Carries Diseases
4.5 Therapeutic Vaccines
4.5.1 Therapeutic Vaccine Trends
5. Leading Vaccines: Revenue Forecasts, 2016-2026
5.1 Prevnar - Pneumococcal Pneumonia
5.2 Gardasil – HPV
5.3 Fluzone – Influenza
5.4 Pentacel – DtaP, Polio, HiB
5.5 ProQuad / M-M-R II / Varivax – Varicella/Chickenpox, Measles, Mumps, Rubella.
5.6 Infanrix/Pediarix – Diptheria, Tetanus and Acellular Pertussis
5.7 Zostavax – Herpes
5.8 RotaTeq – Rotavirus
5.9 GSK Hepatitis Franchise – Hepatitis A & B
5.10 Menactra – Meningococcal
6. Leading Developed National Vaccines Markets, 2016-2026
6.1 The United States Vaccines Markets, 2016-2026
6.1.1 The US Vaccine Market, 2016
6.1.2 The US Vaccine Market Forecast, 2016-2026
6.2 Japanese Vaccines Market, 2016-2026
6.2.1 The Japanese Vaccine Market, 2016
6.2.2 The Japanese Vaccine Market Forecast, 2016-2026
6.2.3 Addressing the Alleged Vaccine Gap
6.3 EU5 Vaccine Market, 2016-2026
6.3.1 The EU5 Vaccine Market, 2016
6.3.2 The EU5 Vaccine Market Forecast, 2016-2026
6.4 United Kingdom Vaccine Market, 2016-2026
6.4.1 The UK Vaccine Market, 2016
6.4.2 The UK Vaccine Market Forecast, 2016-2026
6.5 France: Vaccine Market, 2016-2026
6.5.1 The French Vaccine Market, 2016
6.5.2 The French Vaccine Market Forecast, 2016-2026
6.5.3 French Healthcare System – Immunization Policy
6.6 Germany: Vaccine Market, 2016-2026
6.6.1 The German Vaccine Market, 2016
6.6.2 The German Vaccine Market Forecast, 2016-2026
6.7 Italy: Vaccine Market, 2016-2026
6.7.1 The Italian Vaccine Market, 2016
6.7.2 The Italian Vaccine Market Forecast, 2016-2026
6.7.3 Challenges in Public Healthcare
6.8 Spain: Vaccine Market 2016-2026
6.8.1 The Spanish Vaccine Market, 2016
6.8.2 The Spanish Vaccine Market Forecast, 2016-2026
6.8.3 District Rules – Economic Challenges
7. Leading Emerging National Markets, 2016-2026
7.1 China: Vaccine Market, 2016-2026
7.1.1 The Chinese Vaccine Market, 2016
7.1.2 The Chinese Vaccine Market Forecast, 2016-2026
7.1.3 Setting-Up Domestic Vaccine Industries
7.2 India: Vaccine Market, 2016-2026
7.2.1 The Indian Vaccine Market, 2016
7.2.2 The Indian Vaccine Market Forecast, 2016-2026
7.2.3 The Extent to which the Vaccine Market Can Flourish?
7.3 Brazil: Vaccine Market, 2016-2026
7.3.1 The Brazilian Vaccine Market, 2016
7.3.2 The Brazilian Vaccine Market Forecast, 2016-2026
7.3.3 Zika Outbreak
7.4 Russia: Vaccine Market, 2016-2026
7.4.1 The Russian Vaccine Market, 2016
7.4.2 The Russian Vaccine Market Forecast, 2016-2026
7.4.3 Power of the State
8. Leading Manufacturers of Vaccines for Human Use
8.1 GlaxoSmithKline (GSK)
8.1.1 GSK Vaccine Performance
8.1.2 GSK Developments
8.1.2.1 Mergers and Acquisitions
8.1.2.2 GSK Vaccine Pipeline
8.2 Merck & Co.
8.2.1 Merck Vaccine Performance
8.2.2 Merck Developments
8.2.2.1 Merck Market Movements
8.2.2.2 Collaborations
8.2.2.3 Merck Pipeline
8.3 Sanofi
8.3.1 Sanofi Vaccine Performance
8.3.2 Sanofi Developments
8.3.2.1 Mergers & Acquisitions
8.3.2.2 Sanofi Vaccine Pipeline
8.4 Pfizer
8.4.1 Pfizer Vaccine Performance
8.4.2 Pfizer Developments
8.4.2.1 Pfizer Mergers & Acquisitions
8.4.2.2 Pfizer Pipeline
8.5 Johnson & Johnson
8.6 AstraZeneca
8.7 Other Companies Serving the Vaccines Market
9. Research and Development, 2016
9.1 Prophylactic Vaccines R&D Pipeline
9.1.1 Paediatric Vaccines R&D Pipeline
9.1.2 Adult Vaccines R&D Pipeline
9.1.3 Elderly Vaccines R&D Pipeline
9.1.4 Travel Vaccines R&D Pipeline
9.2 Therapeutic Vaccines R&D Pipeline
10. Qualitative Analysis of the World Vaccines Market, 2016-2026
10.1 SWOT Analysis of the World Human Vaccines Market, 2016
10.1.1 Strengths
10.1.1.1 Ageing Population
10.1.1.2 Prevention is Better than Cure
10.1.1.3 Demand from Emerging Markets Continue
10.1.1.4 Promising R&D Pipeline
10.1.1.5 Increasing Awareness
10.1.2 Weaknesses
10.1.2.1 High Manufacturing Costs
10.1.2.2 Time Constraints
10.1.2.3 Barriers to Market Entry
10.1.3 Opportunities
10.1.3.1 Constant Improvements in Vaccine Technology and Delivery Methods
10.1.3.2 Shifting Focus on Adults Vaccines
10.1.4 Threats
10.1.4.1 Oligarchic Presence of Pharmaceutical Giants
10.1.4.2 Productivity Gap
10.2 STEP Analysis of the World Human Vaccines Industry and Market, 2016-2026
10.2.1 Social Factors
10.2.1.1 Maintaining a Healthier Workforce
10.2.1.2 Public Hesitation - Fear of Unwanted Side-Effects
10.2.2 Technological Forces
10.2.2.1 Evolution of Vaccine Technology Pave the Way for Prophylactics and Therapeutics
10.2.3 Economic Factors
10.2.3.1 High Costs of Production
10.2.3.2 Soaring Vaccines Demand from Developing Countries
10.2.4 Political Factors
10.2.4.1 Governments Play Crucial Roles in Vaccination
11. Conclusions
11.1 Segment Market Share Shift
11.2 Elderly People Become the New Target Market
11.3 Endemic Infections Drive Travel Vaccines Growth
11.4 Emerging Markets: High Demand for Vaccines
11.5 Demand in Mature Pharma Markets Continues: in Particular Japan Will Show Sales Growth
11.6 Strong and Diverse Research and Development
11.7 Concluding Remarks
List of Tables
Table 1.1 Selected National Vaccines Markets: Revenues ($bn) and Market Shares (%) by Leading Country, 2014, 2020 and 2026 (Sample)
Table 3.1 The Global Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGRs (%), 2015-2026
Table 4.1 World Vaccines Submarkets: Revenue Forecasts ($bn), 2015-2026
Table 4.2 World Vaccines Submarkets: Market Shares (%), 2015-2026
Table 4.3 World Paediatric Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.4 World Adult Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.5 World Elderly Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 4.6 World Travel Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.1 Prevnar Revenue ($bn), 2011-2014
Table 5.2 Prevnar Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.3 Gardasil Revenue ($bn), 2011-2014
Table 5.4 Gardasil Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.5 Fluzone/Vaxigrip: Revenue ($bn), 2012-2014
Table 5.6 Fluzone Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.7 Pentacel Revenue ($bn), 2012-2014
Table 5.8 Pentacel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.9 ProQuad / M-M-R II / Varivax Revenue ($bn), 2011-2014
Table 5.10 ProQuad / M-M-R II / Varivax Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.11 Infanrix/Pediarix Revenue ($bn), 2012-2014
Table 5.12 Infanrix/Pediarix Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.13 Zostavax Revenue ($bn), 2011-2014
Table 5.14 Zostavax Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.15 RotaTeq Revenue ($bn), 2011-2014
Table 5.16 RotaTeq Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.17 GSK Hepatitis Franchise Revenue ($bn), 2012-2014
Table 5.18 GSK Hepatitis Franchise Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 5.19 Menactra Revenue ($bn), 2012-2014
Table 5.20 Menactra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.1 Leading National Market Revenue Forecasts ($bn), 2015, 2020, 2026
Table 6.2 Leading Developed National Market Revenue Forecasts ($bn), 2015, 2020, 2026
Table 6.3 Leading Developed National Market Shares (%), 2015, 2020, 2026
Table 6.4 The US Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.5 The Japanese Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.6 EU5 Vaccines World Market Shares (%), 2015, 2020, 2026
Table 6.7 EU5 Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.8 The UK Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.9 The French Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.10 The German Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.11 The Italian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 6.12 The Spanish Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.1 Leading Emerging National Market Revenue Forecasts ($bn), 2015, 2020, 2026
Table 7.2 Leading Emerging National Market Shares (%), 2015, 2020, 2026
Table 7.3 The Chinese Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.4 The Indian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.5 The Brazilian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 7.6 The Russian Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026
Table 8.1 GSK Geographic Revenue ($bn), 2014
Table 9.1 Prophylactic Vaccines in Development, 2016
Table 9.2 Paediatric Vaccines in Development, 2016
Table 9.3 Adult Vaccines in Development, 2016
Table 9.4 Elderly Vaccines in Development, 2016
Table 9.5 Travel Vaccines in Development, 2016
Table 9.6 Therapeutic Vaccines in Development, 2016
List of Figures
Figure 1.1 World Vaccines Market Segmentation, 2016
Figure 3.1 Vaccines Market Share within Global Pharmaceutical Market (%), 2016
Figure 3.2 World Vaccines Leading National Market Shares (%), 2015
Figure 3.3 World Vaccines Leading National Market Shares (%), 2020
Figure 3.4 World Vaccines Leading National Market Shares (%), 2026
Figure 3.5 World Vaccines Market: Drivers and Restraints, 2016-2026
Figure 4.1 World Prophylactic Vaccines Submarket (%) Segmentation, 2015
Figure 4.2 World Paediatric Vaccines Market Share (%), 2014
Figure 4.3 World Paediatric Vaccines Market Share (%), 2020
Figure 4.4 World Paediatric Vaccines Market Share (%), 2026
Figure 4.5 World Paediatric Vaccines Revenue Forecast ($bn), 2015-2026
Figure 4.6 World Adult Vaccines Market Share (%), 2014
Figure 4.7 World Adult Vaccines Market Share (%), 2020
Figure 4.8 World Adult Vaccines Market Share (%), 2026
Figure 4.9 World Adult Vaccines Revenue Forecast ($bn), 2015-2026
Figure 4.10 World Elderly Vaccines Market Share (%), 2014
Figure 4.11 World Elderly Vaccines Market Share (%), 2020
Figure 4.12 World Elderly Vaccines Market Share (%), 2026
Figure 4.13 World Elderly Vaccines Revenue Forecast ($bn), 2015-2026
Figure 4.14 World Travel Vaccines Market Share (%), 2014
Figure 4.15 World Travel Vaccines Market Share (%), 2020
Figure 4.16 World Travel Vaccines Market Share (%), 2026
Figure 4.17 World Travel Vaccines Revenue Forecast ($bn), 2015-2026
Figure 5.1 Prevnar Revenue Forecast ($bn), 2015-2026
Figure 5.2 Gardasil Revenue Forecast ($bn), 2015-2026
Figure 5.3 Fluzone Revenue Forecast ($bn), 2015-2026
Figure 5.4 Pentacel Revenue Forecast ($bn), 2015-2026
Figure 5.5 ProQuad / M-M-R II / Varivax Revenue Forecast ($bn), 2015-2026
Figure 5.6 Infanrix/Pediarix Revenue Forecast ($bn), 2015-2026
Figure 5.7 Zostavax Revenue Forecast ($bn), 2015-2026
Figure 5.8 RotaTeq Revenue Forecast ($bn), 2015-2026
Figure 5.9 GSK Hepatitis Franchise Revenue Forecast ($bn), 2015-2026
Figure 5.10 Menactra Revenue Forecast ($bn), 2015-2026
Figure 6.1 The US Vaccines Revenue Forecast ($bn), 2015-2026
Figure 6.2 The Japanese Vaccines Revenue Forecast ($bn), 2015-2026
Figure 6.3 EU5 Vaccines Market Share (%), 2015
Figure 6.4 EU5 Vaccines Market Share (%), 2020
Figure 6.5 EU5 Vaccines Market Share (%), 2026
Figure 6.6 The UK Vaccines Revenue Forecast ($bn), 2015-2026
Figure 6.7 The French Vaccines Revenue Forecast ($bn), 2015-2026
Figure 6.8 The German Vaccines Revenue Forecast ($bn), 2015-2026
Figure 6.9 The Italian Vaccines Revenue Forecast ($bn), 2015-2026
Figure 6.10 The Spanish Vaccines Revenue Forecast ($bn), 2015-2026
Figure 7.1 BRIC Countries Vaccines Market Share (%), 2015
Figure 7.2 BRIC Countries Vaccines Market Share (%), 2020
Figure 7.3 BRIC Countries Vaccines Market Share (%), 2026
Figure 7.4 The Chinese Vaccines Revenue Forecast ($bn), 2015-2026
Figure 7.5 The Indian Vaccines Revenue Forecast ($bn), 2015-2026
Figure 7.6 The Brazilian Vaccines Revenue Forecast ($bn), 2015-2026
Figure 7.7 The Russian Vaccines Revenue Forecast ($bn), 2015-2026
Figure 8.1 GSK Vaccines Revenue ($bn), 2012-2014
Figure 8.2 GSK Vaccines Region Breakdown (%), 2015
Figure 8.3 Merck Vaccines Revenue ($bn), 2011-2014
Figure 8.4 Sanofi Vaccines Revenue ($bn), 2012-2014
Figure 10.1 SWOT Analysis of the World Vaccines Market, 2016
Figure 10.2 STEP Analysis of the World Vaccines Market, 2016
Companies Listed
Aduro Biotech
Advisory Committee for Immunization Practices (ACIP)
Aspen
Astellas
Asterias Biotherapeutics
AstraZeneca
Bavarian Nordic
Baxter
Bayer
Bharat Biotech
Bill & Melinda Gates Foundation
Binnopharm
BiondVax
BravoBio
Brazilian Universal Health Service
Butantan Institute
Cancer Research UK
Center for Biologics Evaluation and Research (CBER)
Centers for Disease Control and Protection (CDC)
China National Biotec Group
China’s National Regulatory Authority (CNRA)
Chinese Food and Drug Administration (CFDA)
Crucell
Developing Countries Vaccine Manufacturers Network (DCVMN)
Dubai Investments PJSC
Eli Lilly
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Fresenius
GlaxoSmithKline (GSK)
Global Alliance for Vaccines and Immunization (GAVI)
Globalpharma
Health Service Bureau
Henogen
HIV Vaccines Trial Network
Immatics
Indian Department of Biotech
InnoPharma
Inovio Pharmaceuticals
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
International Medica Foundation
InterveXion Therapeutics
Inviragen
Johnson & Johnson
Krka
LigoCyte Pharmaceuticals
Lupin Pharmaceutical
MedImmune
Merck & Co.
Ministry of Health, Labour and Welfare
NewLink Genetics
Novartis
Okairos
Pan American Health Alliance (PAHO)
Pfizer
Profectus BioSciences
Regulus Therapeutics
Roche
Rosteh
Sanofi Pasteur
Servizio Sanitario Nazionale (SSN)
Shanghai BravoBio
Shionogi
Sistema Único de Saúde (SUS)
Takeda
Themis Bioscience
UK National Health Service (NHS)
Unicef
US Department of Health and Human Services (HHS)
US National Cancer Institute
World Health Organization (WHO)
Zymeworks